All Persons who purchased or otherwise acquired Cardinal Health, Inc. Common Stock during the period between March 2, 2015 and May 2, 2018, Inclusive, and were allegedly damaged thereby, and are not otherwise excluded from the settlement class.

Cardinal Health, Inc. Common Stock

The complaint alleges that throughout the class period, defendants made false or misleading statements about Cardinal’s Cordis Corporation, a global manufacturer of cardiology and endovascular devices which Cardinal acquired for $1.9 billion from Johnson & Johnson in October 2015.Specifically, defendants misrepresented that they conducted adequate due diligence of Cordis, and that Cardinal was able to implement, and was implementing, its supply chain expertise and inventory management solutions worldwide at Cordis, which would drive sales growth and reduce any of Cordis’s expired and lost products, and lower Cordis’s managed inventory levels.

Class action brought on behalf of all purchasers of Cardinal common stock between March 2, 2015 and May 2, 2018. The claims asserted herein are alleged against Cardinal and certain of the Company’s senior executives, and arise under Sections 10(b) and 20(a) of the Securities and Exchange Act of 1934.